BSE Pharma Sector Regulatory Filings — May 26, 2026

Q4 FY26 revenue grew 11.8% YoY to INR3,443 crore, with domestic revenue up 13.4%, indicating strong core market demand and market share gains

Adjusted EBITDA margin expanded 400 bps YoY to 27.1% in Q4, the highest in recent quarters, driven by operating leverage and cost controls

Full-year FY26 revenue grew 17.0% to INR14,278 crore, outperforming the broader pharma sector average growth of ~10-12%

Finance costs declined 9.6% QoQ to INR142 crore in Q4 due to repayment of INR1,500 crore commercial papers, signaling improved balance sheet management

Effective tax rate dropped to 16.9% in FY26 from 20.3% in FY25, a 340 bps reduction that provides a structural tailwind to net earnings

Full-year PAT declined 3.4% to INR1,938 crore despite 17% revenue growth, as depreciation surged 42.7% to INR886 crore due to BSV asset consolidation

International revenue grew only 4% in Q4, significantly lagging domestic growth of 13.4%, highlighting vulnerability to geopolitical headwinds in export markets

Insider transaction is a non-event with zero change in promoter shareholding, providing no actionable signal for investors

Full-year PAT declined 3.4% despite 17% revenue growth, indicating that bottom-line growth is not keeping pace with top-line expansion—a potential red flag for earnings quality

Depreciation jumped 42.7% YoY to INR886 crore in FY26 due to full-year impact of BSV assets; this elevated D&A is likely to persist for 2-3 years, pressuring net margins

International revenue growth of just 4% in Q4 vs 13.4% domestic suggests over-reliance on the Indian market; any slowdown in domestic demand would have outsized impact

The company explicitly cited geopolitical issues for weak international performance; ongoing tensions could further depress export revenues in FY27

While Q4 finance costs declined, the company had to repay INR1,500 crore in CPs to achieve this; any future need for short-term borrowing could reverse this trend

No explicit forward guidance was provided in the filing; the absence of a clear outlook for FY27 creates uncertainty around sustainability of margin expansion

The insider transaction provides zero actionable intelligence; investors should not interpret this as any indication of management sentiment

Q4 EBITDA margin of 27.1% (up 400 bps YoY) suggests the company is achieving significant operating leverage; if this trend sustains into FY27, EPS could surprise positively

The repayment of INR1,500 crore commercial papers in Q4 signals a deleveraging trend; further debt reduction could lower finance costs by 10-15% in FY27, boosting net profit

Effective tax rate declined to 16.9% in FY26 from 20.3% in FY25; if sustained, this 340 bps reduction adds ~INR65 crore to net profit annually

Domestic revenue growth of 13.4% in Q4 outpaces the Indian pharma market growth of ~8-10%, indicating market share gains in the chronic therapy segment

The full-year impact of BSV assets is now reflected in FY26 D&A; as integration synergies materialize in FY27, operating margins could expand further beyond the 27.1% Q4 level

With Q4 EBITDA margin at 27.1% and revenue growing 17% YoY, the stock may be undervalued relative to peers trading at 25-30x P/E; a re-rating could occur if margin sustainability is demonstrated

The filing confirms stable promoter holding; investors can ignore this event and focus on Zydus's upcoming earnings for actionable insights

Mankind Pharma's 400 bps margin expansion contrasts with a 3.4% PAT decline, highlighting a sector-wide theme where strong operational performance is being offset by higher depreciation (from M&A/expansion) and finance costs. Investors should focus on EBITDA rather than PAT for true operating health.

Mankind's domestic revenue grew 13.4% in Q4 vs international at 4%, reinforcing a sector trend where Indian pharma companies are benefiting from chronic disease demand and government healthcare spending, while export markets face pricing pressure and geopolitical uncertainty.

Mankind's repayment of INR1,500 crore CPs signals a shift from aggressive expansion to balance sheet consolidation. This may be a broader sector trend as companies prioritize debt reduction after recent M&A sprees (e.g., BSV acquisition).

Zydus's routine promoter transmission underscores that not all insider filings are material. Investors should differentiate between genuine insider trades (market purchases/sales) and administrative transfers to avoid false signals.

Mankind's effective tax rate dropped to 16.9% from 20.3%, likely due to tax incentives from new manufacturing units. This could be a sector-wide trend as companies set up plants under production-linked incentive (PLI) schemes, providing a 300-400 bps tax tailwind.

Watch for sustainability of 27%+ EBITDA margin and any improvement in international revenue growth; expected around mid-August 2026

Monitor if D&A stabilizes in FY27 or continues to rise; any decline would be a strong positive catalyst for EPS

Track further debt repayment plans; the company's ability to reduce finance costs further will be key to PAT recovery

Watch for commentary on geopolitical headwinds easing; any pickup in export growth would be a significant positive

Scheduled analyst/investor meet to discuss Q4 results; listen for FY27 guidance on revenue growth and margin targets

While today's filing is a non-event, Zydus's Q4 FY26 results are expected in the coming weeks; watch for similar margin trends and international performance

Monitor if any other BSE PHARMA companies report insider buying/selling in the coming weeks; a cluster of insider sales in the sector would be a bearish signal

Watch for any other pharma companies announcing debt reduction plans, which could signal a sector-wide deleveraging theme